CN104366636B - A kind of Gynura procumbens (Lour.) Merr. compound formulation and preparation method and application - Google Patents
A kind of Gynura procumbens (Lour.) Merr. compound formulation and preparation method and application Download PDFInfo
- Publication number
- CN104366636B CN104366636B CN201410593469.0A CN201410593469A CN104366636B CN 104366636 B CN104366636 B CN 104366636B CN 201410593469 A CN201410593469 A CN 201410593469A CN 104366636 B CN104366636 B CN 104366636B
- Authority
- CN
- China
- Prior art keywords
- lour
- merr
- gynura procumbens
- compound formulation
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 240000008672 Gynura procumbens Species 0.000 title claims abstract description 62
- 235000018457 Gynura procumbens Nutrition 0.000 title claims abstract description 62
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 150000001875 compounds Chemical class 0.000 title claims abstract description 39
- 238000009472 formulation Methods 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 239000002994 raw material Substances 0.000 claims abstract description 33
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 27
- 239000003814 drug Substances 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000008187 granular material Substances 0.000 claims description 16
- 238000001816 cooling Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 241000196324 Embryophyta Species 0.000 claims description 7
- 210000000582 semen Anatomy 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 230000018044 dehydration Effects 0.000 claims description 5
- 238000006297 dehydration reaction Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 244000268590 Euryale ferox Species 0.000 claims description 3
- 235000006487 Euryale ferox Nutrition 0.000 claims description 3
- 239000009636 Huang Qi Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 57
- 201000005569 Gout Diseases 0.000 abstract description 53
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 42
- 229940116269 uric acid Drugs 0.000 abstract description 42
- 230000000694 effects Effects 0.000 abstract description 28
- 210000004369 blood Anatomy 0.000 abstract description 24
- 239000008280 blood Substances 0.000 abstract description 24
- 239000013078 crystal Substances 0.000 abstract description 12
- 230000029142 excretion Effects 0.000 abstract description 11
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 230000036541 health Effects 0.000 abstract description 9
- 230000004060 metabolic process Effects 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 8
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 230000000202 analgesic effect Effects 0.000 abstract description 7
- 230000033228 biological regulation Effects 0.000 abstract description 6
- 208000006820 Arthralgia Diseases 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 230000008961 swelling Effects 0.000 abstract description 4
- 235000013361 beverage Nutrition 0.000 abstract description 2
- 229930014626 natural product Natural products 0.000 abstract description 2
- 238000004321 preservation Methods 0.000 abstract description 2
- 238000005728 strengthening Methods 0.000 abstract 1
- 238000005303 weighing Methods 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 15
- 230000036407 pain Effects 0.000 description 14
- 210000003734 kidney Anatomy 0.000 description 12
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 10
- 210000002700 urine Anatomy 0.000 description 9
- 230000001154 acute effect Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 230000008021 deposition Effects 0.000 description 7
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 6
- 201000001431 Hyperuricemia Diseases 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 206010018634 Gouty Arthritis Diseases 0.000 description 5
- 206010042674 Swelling Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000005239 tubule Anatomy 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960001338 colchicine Drugs 0.000 description 3
- 238000005202 decontamination Methods 0.000 description 3
- 230000003588 decontaminative effect Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 210000000629 knee joint Anatomy 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010033425 Pain in extremity Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 206010046337 Urate nephropathy Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000026816 acute arthritis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000003797 carpal joint Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000002485 combustion reaction Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000005453 pelletization Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000004144 purine metabolism Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002522 swelling effect Effects 0.000 description 2
- 210000001258 synovial membrane Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 208000013824 Acidemia Diseases 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010051779 Bone marrow toxicity Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028034 Mouth ulceration Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 231100000366 bone marrow toxicity Toxicity 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 210000001513 elbow Anatomy 0.000 description 1
- 210000002310 elbow joint Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- BUKHSQBUKZIMLB-UHFFFAOYSA-L potassium;sodium;dichloride Chemical compound [Na+].[Cl-].[Cl-].[K+] BUKHSQBUKZIMLB-UHFFFAOYSA-L 0.000 description 1
- 238000012913 prioritisation Methods 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000323 shoulder joint Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/34—Tea substitutes, e.g. matè; Extracts or infusions thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pediatric Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to field of health-care beverage, particularly to a kind of Gynura procumbens (Lour.) Merr. compound formulation and preparation method and application.It is characterized in that: described compound preparation is made up of following percentage by weight raw material: Gynura procumbens (Lour.) Merr. 75 85%, Herba Hordei Vulgaris 5 10%, Herba Lophatheri 3 6%, Folium Mori 2 5%, Radix Puerariae 2 4%, Poria 1 3%, Gynura procumbens (Lour.) Merr. first passes through weighing, fire dry, little forms with other raw material co-grinding step weighed after bakeing.Preparation safety, health, natural, there is comprehensive, the multipath treatment gout of multiple efficacies, gout can be played regulation uric acid metabolism, promote urate excretion, prevent uric acid crystal, anti-inflammatory analgetic, control stage of attack arthralgia, swelling and the effect of inflammation, and reduce blood-fat and blood sugar, strengthening renal metabolism, treating both the principal and secondary aspects of a disease reaches anti-antipodagric effect, has the feature of natural compound recipe, natural Health preservation.Preparation method is simple, convenient, and maximum maintains original composition of raw material.
Description
Technical field
The invention belongs to field of health-care beverage, particularly to a kind of Gynura procumbens (Lour.) Merr. compound formulation and preparation method and should
With.
Background technology
In recent years, gout has become the affluenza that sickness rate is the highest.Gout is also known as " hyperuricemia "
Owing to biosynthesis of purine metabolism increases, uric acid produces too much or because renal excretion uric acid reduces, and causes metabolic arthritis
Mass formed by blood stasis, when serum Uric Acid Concentration is too high, uric acid is deposited in joint, cartilage and kidney with the form of sodium salt, causes tissue foreign body scorching
Disease is reacted.Gout often accompanies abdominal obesity, saccharide disorders of lipid metabolism, hypertension, arteriosclerosis and cardiovascular diseases etc. to assemble generation.
Traditional treatment medicine is Western medicine, the symptom selective therapy showed for patient with gout different times, but generally
There is serious toxic and side effects, as anti-inflammation analgesis medicament colchicine for acute attack stage can pain relieving rapidly, but to bone marrow, liver
Dirty, kidney has overt toxicity, can cause leukemia；Excretion uric acid medicine probenecid was treated for intermission and chronic phase, but right
Gastrointestinal tract responds and swashs gouty attack,acute；Allopurinol is as the medicine of prevention gout outbreak, to hepatic and renal function and bone marrow
Toxicity also make medical circle to promote；Other also can only be " treat the head when the head aches, foot pain cures foot " such as antiinflammatory, hormone medicine
Interim pain relieving, and toxic and side effects is the most clearly, causes the awkward situation of " take medicine and be impairment of the kidney, do not eat recurrence ".
Because Western medicine side effect is big, in addition it is also necessary to strictly aviod certain food, patient with gout is difficult to adhere to taking.And conventional medicament typically can only
Single pain relieving deacidification, and to gout complication (gouty hypertension, diabetes, sclerosis of blood vessels and hyperlipidemia, lithangiuria)
Feel simply helpless, can only develop as one pleases.A lot of patient pain unbearably, want by surgery treatment gout, but operation cure rate
The lowest, postoperative recurrence frequency is high, produces multiple complications, causes body and mind more major injury.
These are the most defective in treatment, and kind is few, narrow application range, weak curative effect, side effect become greatly its clinical practice
Bottleneck.Treatment gout makes medical circle in a dilemma, and patient with gout the most finally can not break away from wrecking of the serious illness.
Along with economic development and lifestyle change, its prevalence is gradually increasing.According to statistics, existing nearly 90,000,000 pains of China
Wind patient, potential patient 1.2 hundred million, 90% concentrates on the male between 25 65 years old, gout sickness rate also with annual 10% speed
Degree rising year by year and the trend in rejuvenation, become second largest and threatened human life and healthy metabolic system disease.
Therefore, its Drug therapy and new drug development the most increasingly cause the attention of people.Therefore gout class medicine is at me
State's market potential is very big, but gout class medicine in the market mostly is old medicine, imitation medicine, expensive and side effect is bright
Aobvious.Can the novel drugs of solution gout problem comprehensive, safe and effective release if had, market prospect is by considerable in good time.
Summary of the invention
In order to solve above technical problem, the present invention provides a kind of Gynura procumbens (Lour.) Merr. compound formulation and preparation method and answers
With, preparation safety, health, natural, there is multiple efficacies, be applied to comprehensive, multipath anti-treatment gout, gout can be played
Regulation uric acid metabolism, promotes urate excretion, prevents uric acid crystal, anti-inflammatory analgetic, controls stage of attack arthralgia, swelling and inflammation
The effect of disease, decrease blood lipid blood glucose, strengthen renal metabolism, also there is the feature of natural compound recipe, natural Health preservation.Preparation method
Simply, conveniently, maximum maintains original composition of raw material, green natural.
Solve a kind of Gynura procumbens (Lour.) Merr. compound formulation in the present invention of above technical problem, it is characterised in that: described multiple
Side closes preparation and is made up of following percentage by weight raw material: Gynura procumbens (Lour.) Merr. 75-85%, Herba Hordei Vulgaris 5-10%, Herba Lophatheri 3-6%, frost Mulberry
Leaf 2-5%, Radix Puerariae 2-4%, Poria 1-3%.
Compound formulation described in prioritization scheme is made up of following percentage by weight raw material: Gynura procumbens (Lour.) Merr. 77-82%, Fructus Hordei Vulgaris
Seedling 5-8%, Herba Lophatheri 4-5%, Folium Mori 2-4%, Radix Puerariae 2-3%, Poria 2-3%.
Further, more excellent scheme can be made up of following percentage by weight raw material by described compound formulation: Gynura procumbens (Lour.) Merr. 80%,
Herba Hordei Vulgaris 8%, Herba Lophatheri 4%, Folium Mori 3%, Radix Puerariae 3%, Poria 2%.
Gynura procumbens (Lour.) Merr.: Gynura procumbens (Lour.) Merr. is the health care plant of dietotherapeutic, containing multiple flavone, steroid, green
Ortho acid, linoleic acid plus linolenic acid and water soluble dietary fiber.Dredge the meridian passage, anti-inflammatory analgetic；Anti-nucleic acid aoxidizes, and suppression purine is raw
Become, promote urate excretion, alleviate gout, protect the liver and protect kidney.Blood uric acid can be reduced at metabolic arthritis asymptomatic stage, promote uric acid metabolism,
Prevent uric acid crystal, dissolve the urate calculus formed, simultaneously can anti-inflammatory analgetic, control stage of attack arthralgia, swelling
And inflammatory reaction, the gout of acute stage and intermission there is is improvement result, to reducing blood fat, vessel softening, reducing blood pressure, promote
Enter microcirculatory effect.
Herba Hordei Vulgaris: Herba Hordei Vulgaris rich in mineral substances, can effectively neutralize the body fluid of human body slant acidity day by day and be referred to as, and " alkalescence is eaten
The king of product ".Patient with gout itself has purine metabolic disturbance uric acid abnormal, if too much eating acid food can increase the weight of the state of an illness, unfavorable
In rehabilitation, and eat base-forming food more and can help to supplement potassium sodium chloride ion, maintain acid-base balance, be eaten for a long time can alkalize blood and urine
Liquid, reduces blood uric acid, increases urate excretion, neutralizes being deposited on the urate crystal at joint, soft tissue, dissolve, discharges, from
And it is effectively reduced gout outbreak.
Herba Lophatheri: heat clearing away, damp eliminating diuresis, get rid of uric acid.There is effect of the relieving restlessness that clears away heart-fire, inducing diuresis for treating stranguria syndrome, accelerate uric acid with
Urine is discharged, and can be used for the diseases such as calentura restlessness and thirst, spiritlessness and weakness, hot urination, aphtha of the mouth and tongue.
Folium Mori: antiinflammatory heat clearing away, diuretic purifies the blood；Diuretic effect is different from diuresis, not only can promote to urinate, also may be used
So that the excessive moisture amassed in cell is drained.
Radix Puerariae: containing compositions such as Radix Puerariae flavone, daucosterol, aminoacid, uric acid can be suppressed to be formed, blood vessel can be expanded again,
Improving blood circulation of kidney, preventing and treating uric acid crystal amasss in subcutaneous, among thin vessels and joint.
Poria: vessel softening, reduces blood fat, regulates acid-base balance, promotes internal homergy.
The preparation method of medicine composite preparation in Gynura procumbens (Lour.) Merr. in the present invention, it is characterised in that: comprise the following steps:
(1) prepare raw material and weigh: choosing fresh, clean Gynura procumbens (Lour.) Merr. base of leaf and whole plant, cleaning and sterilizing；
(2) it is dried, 45-55 DEG C, 30-40min；
(3) calculate with fresh Gynura procumbens (Lour.) Merr. weight, when Gynura procumbens (Lour.) Merr. dehydration is to water content 55-63%, be cut into 0.7-
The sections of 1.5cm length, less fire bakee, when water content 5-10%, and slightly burnt odor taste time stop bakee, standby after cooling, this
Time sections can be fractureed easily；
It is dewatered to 55-63%, makes most of moisture be removed, it is simple to during parch, moisture evaporates faster, time-consuming and combustion
Material.Until sections can be fractureed easily, it is simple to preserve for a long time.Slightly burnt odor taste, makes mouthfeel more preferable.
(4) by the Gynura procumbens (Lour.) Merr. after cooling in Herba Hordei Vulgaris, Herba Lophatheri, Folium Mori, Radix Puerariae, Poria and step (3) respectively
It is ground into granule, remixes uniformly；
(5) by the composition of medicine of above-mentioned mix homogeneously, then teabag, oral liquid, capsule, tablet, powder it are fabricated on request
End, granule or the compound formulation of other pharmaceutically acceptable dosage form.
Described sections is the sections of 0.7-1.5cm length.
Grain diameter in described step (4) is 1-6mm.
Described Herba Lophatheri replaces with Rhizoma Imperatae, Semen Coicis or Stigma Maydis, and Folium Mori replaces with Herba Plantaginis or Herba Lysimachiae.
Described Radix Puerariae replaces with Rhizoma Dioscoreae or the Cortex Eucommiae, and Poria replaces with the Radix Astragali or Semen Euryales.
Needing to pick decontamination before raw material chopping, when pulverizing is to use, nutritional labeling separates out more abundant, and granule is too big, becomes
Dividing and be not easy all to discharge, granule is the least, easily makes soup color muddy, affects mouthfeel.Or conveniently make when making other dosage form
With.
Described compound formulation in the present invention can be applicable to prevent and treat gout.
The mechanism produced according to uric acid, has prevented and treated gout and will reduce the generation of uric acid, reduced internal purine, add simultaneously
The eliminating of strong uric acid.Traditional gout medicine, such as colchicine, has overt toxicity to bone marrow, Liver and kidney.All gout patients all faces
Face the dilemma of " fearness of taking medicine is harmful to the health, and does not eat and is afraid of recurrence ".Cure the symptoms, not the disease, can only temporary alleviating pain, enter gout
Non-evident sympton after intermission, but internal uric acid continues higher, the most easily delays the best opportunity for the treatment of.The compound recipe of the present invention
Pharmaceutical formulation carries out overall co-ordination from raw material and consumption, and producing the i.e. uric acid of principle according to gout increases and metabolic stress, from urine
Nursing one's health in the generation of acid and excretion system, reduce uricopoiesis, deacidification blood fat reducing is supported kidney triple effect and is unified, treating both the principal and secondary aspects of a disease, thus
Reach the purpose of invention.Such as not having Gynura procumbens (Lour.) Merr.: anti-inflammatory analgesic effect is inconspicuous, uric acid level and blood pressure and blood lipoid reduce width
Spend inconspicuous.There is no Herba Hordei Vulgaris: the PH value of uric acid is higher, and fall is the biggest.Wherein, Gynura procumbens (Lour.) Merr., suppression purine produces
Raw, prevent uric acid crystal, anti-inflammatory analgesic；Herba Hordei Vulgaris, balance blood and urine pH value；Folium Mori, releasing uric acid；Herba Lophatheri, profit
Urine；Gynura procumbens (Lour.) Merr., Radix Puerariae, Poria, strengthen renal metabolism.Work in coordination with onset through scientific compatibility, be different from conventional medicament " headache doctor
Head, foot pain doctor foot " interim pain relieving, but from source solve gout problem, more can be prevented effectively from gout recurrence.Can be the most clear
Except interior free yl, get rid of vivotoxin, antioxidation, remove cholesterol, promote sugar metabolism, reduce blood glucose and glucose in urine, opposing
Various toxin, to kidney and the injury of nervus centralis, stop the generation of complication.
Compound preparation in the present invention uses the health care plant of dietotherapeutic, it then follows the nourishing healthy reason of integration of edible and medicinal herbs
Read, in conjunction with other natural drug, natural curing, safe no dependence, and there is good health-care effect, be more suitable for patient with gout
And high-risk group's long-term taking.Retaining natural nutrient component, superelevation absorption rate, mouthfeel is more preferable, and effect becomes apparent from comprehensively.
Total effect:
1. regulation human body purine metabolism, reduces the synthesis of purine, effectively controls metabolic arthritis；
2. alkalization blood and urine pH value, promotes uricolysis and excretion, reduces blood uric acid, prevents gout from showing effect；
The most effectively dissolving urate calculus, prevent uric acid crystal, destruction of joint and kidney that prevention urate deposition causes damage
Evil；
4. anti-inflammation detumescence, dredge the meridian passage, control arthralgia, swelling and inflammatory reaction, prevent gouty arthritis；
5. regulation blood fat, blood glucose, maintenance cardiovascular and cerebrovascular vessel are healthy, prevent gout complication；
The most balanced nutritious, improve metabolism, enhancing immunity, promote body energy.
The present invention has quick-acting antalgesic, promotes human acid-base balance, dredges renal excretion uric acid effect, can substantially recover blood
Uric acid level, reduces the recurrent exerbation of gout, advantage without any side effects and effect.And preparation technology is simple, raw material
Source is wide, it is easy to accomplish industrial scale produces
Detailed description of the invention
Embodiment 1
Compound formulation is made up of following percentage by weight raw material: Gynura procumbens (Lour.) Merr. 75, Herba Hordei Vulgaris 10, Herba Lophatheri 5, Folium Mori
4, Radix Puerariae 3, Poria 3, manufacture method comprises the following steps:
(1) prepare raw material and weigh: choosing fresh, clean Gynura procumbens (Lour.) Merr. base of leaf and whole plant, put into washing
Machine is carried out sterilization with every liter containing 0.8 1.2mg/L Ozone Water；
(2) calculate with fresh Gynura procumbens (Lour.) Merr. weight, be dried, 50 DEG C, 35min；
(3) when making Gynura procumbens (Lour.) Merr. dehydration to water content 55-63%, it is cut into the sections of 1cm length, bakees with the little fire of iron pan,
When water content 5-10%, and slightly burnt odor taste time stop bakee, standby after cooling, now sections can be fractureed easily；
It is dewatered to 55-63%, makes most of moisture be removed, it is simple to during parch, moisture evaporates faster, time-consuming and combustion
Material.Until during moisture 5-10%, it is simple to preserve for a long time.Slightly burnt odor taste, makes mouthfeel more preferable.
(4) by the Gynura procumbens (Lour.) Merr. after cooling in Herba Hordei Vulgaris, Herba Lophatheri, Folium Mori, Radix Puerariae, Poria and step (3) respectively
It is ground into the granule of 5mm length, remixes uniformly；
Raw material is dry product, needs to pick decontamination before chopping.When pulverizing is to use, nutritional labeling separates out more abundant, granule
Too big, composition is not easy all to discharge, and granule is the least, easily makes soup color muddy, affects mouthfeel.
(5) by the composition of medicine of above-mentioned mix homogeneously, load and filter that tea bag is soaked drinks, 5 grams every bag.Three times a day, in early
In each time of evening, each 1 bag, 200ML boiling water brews 5-8 minute offspring's tea-drinking and uses.
Embodiment 2
Compound formulation is made up of following percentage by weight raw material: Gynura procumbens (Lour.) Merr. 85, Herba Hordei Vulgaris 5, Herba Lophatheri 3, Folium Mori
2, Radix Puerariae 2, Poria 3, manufacture method comprises the following steps:
(1) prepare raw material and weigh: choosing fresh, clean Gynura procumbens (Lour.) Merr. base of leaf and whole plant, put into washing
Machine is carried out sterilization with every liter containing 0.8 1.2mg/L Ozone Water；
(2) calculate with fresh Gynura procumbens (Lour.) Merr. weight, be dried, 45 DEG C, 40min；
(3) when making Gynura procumbens (Lour.) Merr. dehydration to water content 60%, it is cut into the sections of 0.7cm length, bakees with the little fire of iron pan,
When water content 5-10%, and slightly burnt odor taste time stop bakee, standby after cooling, now sections can be fractureed easily；
(4) by the Gynura procumbens (Lour.) Merr. after cooling in Herba Hordei Vulgaris, Herba Lophatheri, Folium Mori, Radix Puerariae, Poria and step (3) respectively
It is ground into the granule of 1mm length, remixes uniformly；
(5) by the composition of medicine of above-mentioned mix homogeneously, load and filter that tea bag is soaked drinks, 5 grams every bag.Three times a day, in early
In each time of evening, each 1 bag, 200ML boiling water brews 5-8 minute offspring's tea-drinking and uses.
Embodiment 3
Compound formulation is made up of following percentage by weight raw material: Gynura procumbens (Lour.) Merr. 78, Herba Hordei Vulgaris 6, Herba Lophatheri 6, Folium Mori
5, Radix Puerariae 4, Poria 1, making and use method such as embodiment 1.
Embodiment 4
Compound formulation is made up of following percentage by weight raw material: Gynura procumbens (Lour.) Merr. 82, Herba Hordei Vulgaris 8, Herba Lophatheri 4, Folium Mori
2, Radix Puerariae 2, Poria 2, making and use method such as embodiment 2.
Embodiment 5
Compound formulation is made up of following percentage by weight raw material: Gynura procumbens (Lour.) Merr. 77, Herba Hordei Vulgaris 8, Herba Lophatheri 5, Folium Mori
4, Radix Puerariae 3, Poria 3, manufacture method comprises the following steps:
(1) prepare raw material and weigh: choosing fresh, clean Gynura procumbens (Lour.) Merr. base of leaf and whole plant, put into washing
Machine is carried out sterilization with every liter containing 0.8 1.2mg/L Ozone Water；
(2) calculate with fresh Gynura procumbens (Lour.) Merr. weight, be dried, 55 DEG C, 30min；
(3) when making Gynura procumbens (Lour.) Merr. dehydration to water content 60%, it is cut into the sections of 1.5cm length, bakees with the little fire of iron pan,
Until, sections can be fractureed easily, and similar moisture is completely without, and slightly burnt odor taste, standby after cooling；
It is dewatered to 60%, makes most of moisture be removed, it is simple to during parch, moisture evaporates faster, time-consuming and fuel.Directly
To moisture completely without, it is simple to preserve for a long time.Slightly burnt odor taste, makes mouthfeel more preferable.
(4) by the Gynura procumbens (Lour.) Merr. after cooling in Herba Hordei Vulgaris, Herba Lophatheri, Folium Mori, Radix Puerariae, Poria and step (3) respectively
It is ground into the granule of 4mm length, remixes uniformly；
Raw material is dry product, needs to pick decontamination before chopping.When pulverizing is to use, nutritional labeling separates out more abundant, granule
Too big, composition is not easy all to discharge, and granule is the least, easily makes soup color muddy, affects mouthfeel.
(5) by the composition of medicine of above-mentioned mix homogeneously, putting in tank, the appropriate big fire that adds water is fried boiling, then it is little to decoct half with slow fire
Time, leach medicinal liquid；Add water in medicinal residues and again decoct half an hour, then leach medicinal liquid；Twice medicinal liquid mixing.The morning, afternoon, respectively drank in the evening
With 1 time.
Embodiment 6
Compound formulation is made up of following percentage by weight raw material: Gynura procumbens (Lour.) Merr. 80, Herba Hordei Vulgaris 8, Herba Lophatheri 4, Folium Mori
3, Radix Puerariae 3, Poria 2, content such as embodiment 1 in other preparation method, the composition of medicine of mix homogeneously is ground into 80 mesh powder,
Take sucrose and the dextrin mixed powder (3:1) of powder process again, in one-step-granulating method, be mixed and made into granule.Granule mistake on pelletizing machine
70 mesh sieves, by the granule after whole on pelletizing machine, spray in the volatile oil solution that appropriate ethanol dissolves, mix homogeneously, with
Particle packing machine is packed, 3 grams every bag.Every day 2-3 time, each 1 bag, 30 days be a treatment, and hot water is taken after mixing it with water.
Embodiment 7
Compound formulation is made up of following percentage by weight raw material: Gynura procumbens (Lour.) Merr. 80, Herba Hordei Vulgaris 5, Herba Lophatheri 5, Folium Mori
4, Radix Puerariae 3, Poria 3, other preparation method such as embodiment 1, then the composition of medicine of mix homogeneously is ground into 80 mesh powder, add
8 magnesium stearate, encapsulated after mixing, 1 gram/.Oral every day 2-3 time, each 3,30 days be a course for the treatment of.
Embodiment 8
Compound formulation is made up of following percentage by weight raw material: Gynura procumbens (Lour.) Merr. 80, Herba Hordei Vulgaris 8, Herba Lophatheri 4, Folium Mori
3, Radix Puerariae 3, Poria 2, preparation and application such as embodiment 1.
Embodiment 9
Compound formulation is made up of following percentage by weight raw material: Gynura procumbens (Lour.) Merr. 79, Herba Hordei Vulgaris 8, Herba Lophatheri 4, Folium Mori
3, Radix Puerariae 3, Poria 3, preparation and application such as embodiment 1.
Embodiment 10
Compound formulation is made up of following percentage by weight raw material: Gynura procumbens (Lour.) Merr. 81, Herba Hordei Vulgaris 7, Herba Lophatheri 5, Folium Mori
2, Radix Puerariae 3, Poria 2, preparation and application such as embodiment 1.
Embodiment 11
Compound formulation is made up of following percentage by weight raw material: Gynura procumbens (Lour.) Merr. 81, Herba Hordei Vulgaris 7, Herba Lophatheri 5, Folium Mori
2, Radix Puerariae 3, Poria 2, preparation and application such as embodiment 1.
Embodiment 12
Compound formulation is made up of following percentage by weight raw material: Gynura procumbens (Lour.) Merr. 81, Herba Hordei Vulgaris 7, Rhizoma Imperatae or Stigma Maydis
5, Herba Plantaginis 2, Rhizoma Dioscoreae 3, the Radix Astragali 2, preparation and application such as embodiment 1.
Embodiment 13
Compound formulation is made up of following percentage by weight raw material: Gynura procumbens (Lour.) Merr. 81, Herba Hordei Vulgaris 7, Semen Coicis 5, Herba Lysimachiae 2,
The Cortex Eucommiae 3, Semen Euryales 2, preparation and application such as embodiment 1.
Test 1: the animal toxicity experiment of the present invention
Taking rabbit 20, body weight 2-2.5kg, divide two groups, often group 10, one of which is overdose test group, another group
For normal amount test group.Using and decoct dosage form, the content in embodiment 5 and preparation method, administration by gavage is administered, and super quantity group is
60ml/kg, normal amount is 30ml/kg every day 2 times, continuous 7 days, observes and is administered reaction, showing that two groups of rabbit are movable, diet just
Often, medicine is without bad toxic and side effects.
Test one: efficacy experiment
1, diagnostic criteria
1. asymptomatic hyperuricemia: the generation Chang Shifen of hyperuricemia is hidden to be attacked, the initial stage for be interrupted occur, gradually in
Persistence, is not intended to find when more than health check-up or going to a doctor because other are sick.
2. acute gouty arthritis: this is that gout most has feature and common symptom, and onset is hurried, a few hours it
Interior affected joints i.e. may occur in which obvious redness, burning pain, often in night-time attack, wakes up because of joint severe pain, and local joint is because of pain
Can not touch, even can not lid sheet, limitation of activity.With foot first sole of the foot toe for predilection site, secondly it is other of brothers
Minor articulus, ankle, knee joint, wrist, elbow, shoulder joint.Initial stage mostly is simple joint pathological changes, and both sides alternately occur, and the later stage can be multi-joint pathological changes,
Occur simultaneously or successively.Eating and drinking too much at one meal, insobriety, fatigue, infection, wound, operation, wound, periarticular pressurized, footwear are carried out not
Suitable grade can be all risk factor.Acute attack symptom continues more than one week, the most gradually alleviates.After local joint redness disappears,
Skin can be had to itch, peel, pigmentation.Stage of attack General Symptoms can have heating, weak, increased heart rate, headache etc..
3. the gout intermission: the gout intermission refers to the phase between twice acute gouty arthritis outbreak, short then several weeks, long
Then many decades.Once in a while again without outbreak after the 1st acute arthritis of some patients, majority is from long to short.The intermission state of an illness is relative
Steadily, also known as resting state.Some patients is uncomfortable after can having former affected joints activity, can alleviate after rest.Still can there is high urine
Acidemia, is affected by diet and treatment situation, and serum uric acid level is unstable.
The chronicest gravel gout: long-term hyperuricemia fails to correct, and it is soft that urate crystal can extensively be deposited on joint
Bone, synovial membrane, ligament, subcutaneous, kidney, gradually form urate calculi, heavy then affect the physiological function of deposition fabric.Wherein part
After established calculus uric acid is controlled, still can melt, reduce, even disappear completely, this is that gouty calculus is the most special
Lapse to.
The most subcutaneous tophus tuberosity: be deposited on subcutaneous formation by urate crystal, is apt to occur in helix, joint periphery (toe, refers to
Between joint, knee joint, elbow joint, carpal joint etc.), tuberosity differs in size, Semen Sesami size to 1～2 centimetre greater tubercle, border
Irregularly, matter is hard, and table superficial part position is yellow-white.Tuberosity well-defined with perienchyma, without touching a tender spot, but as merged antibacterial sense
Dye, can have perienchyma's redness, tenderness, have ulceration mouth more.Stone composition is taken out in acupuncture or ulceration secretions microscopy is urate
Crystallization.
6. gouty arthritis,chronic: the repeated multiple times acute arthritis joint tissue fibrosis that causes of outbreak and tophus
In articular cartilage, synovial membrane, the deposition of ligament, make pathological changes joint gradually damaged deformation, lose motor function.Toe, interphalangeal joint,
Ankle, knee joint, carpal joint are easily got involved.
7. chronic gouty nephropathy and renal calculus: urate crystal has 2 kinds of forms in the deposition of kidney, divides including uric acid
Secrete renal tubules apurinic acid mineralization (in medullary interstitium, renal tubules, uric acid concentration is normal) and the interior urine of renal tubules that excretion deficiency causes
Too high can not the discharge in time of acid concentration and urate deposition in the renal tubules that is detained.Chronic Uric-acid Nephropathy can be at both uric acid
Occurring on the basis of deposition pattern in kidney, majority is after the acute gouty arthritis of recurrent exerbation, and minority can only have length
Occur on the basis of phase hyperuricemia.
2, the clinical observation material of Drug therapy gout of the present invention
The patient of this observation totally 58 example, is all male, the oldest person 75 years old, age reckling 24 years old, course of disease elder
27 years, the shortest half a year.
Table 1 patient profiles analyzes
Table 2 first attack cause analysis
Table 3 Analysis On Complications
Other performance of table 4 is analyzed
Table 5 painful area analysis
3, Therapeutic Method
Brew to patient's boiling water and drink product of the present invention, each 1 time of evening in afternoon in the morning, each 1 pouch, within 15 days, it is one
The course for the treatment of, take 6 courses for the treatment of continuously.
4, efficacy assessment standard
Curing: transference cure, body constitution recovers normal, observes half a year without recidivist；
Take a turn for the better: arthroncus is cut down, and pain relief, body constitution is progressively recovered；
Invalid: symptom is unchanged.
5, efficacy analysis
58 example patient with gout, cure 32 examples, cure rate 55%, and take a turn for the better 23 examples, improvement rate 40%, invalid 3 examples, total effective rate
95%。
Table 6 efficacy analysis
Blood uric acid and clinical manifestation analysis before and after table 7 treatment
6, typical case analysis:
Opening xx, man 46 years old, people from Shandong, trade for many years, is busy with one's work, and dinner party is many, often drinks, and suffers from goat 12 years, and four
Limb multi-joint is in persistently showing effect, and length takes colchicine medicine, and unsatisfactory curative effect of in many ways seeing the doctor for treatment takes medicine of the present invention 20 days
Time pain relief, 50 days complete and pain frees, recur the most again.
Fan XX, 52 years old, people from Sichuan, houses market portion was responsible for, and operating pressure is big, often works overtime, and dinner party is many, gout 9 years, table
Existing biped redness and swelling of joints pain outbreak is frequent, and with renal dysfunction.Can stand during acute attack walking, uric acid level 503 μ
mol/L.Taking after the present invention quickly removes joint part uric acid crystal 15 days, pain relief, joint pigment subtracts light, can independent rows
Walking, when taking 35 days, joint part tophus tuberosity is wholly absent, and after taking 90 days, uric acid level reduces to the 390 normal models of μm ol/L
Enclosing, gout recurs the most again, and gout complication also disappears.
The present invention chooses natural Chinese medicines formula, is especially added with this integration of edible and medicinal herbs kind of Gynura procumbens (Lour.) Merr., is used for preventing
With treatment hyperuricemia and the medicine of gout, and the complication causing gout has synergistic therapeutic action, and curative effect shows
Write, stablize, effect that safety has no side effect.The present invention is with low cost, convenient to use, applied widely.
In order to solve above technical problem, the present invention provide a kind of safe and healthy, natural, there is the full side of multiple efficacies
Position, the Gynura procumbens (Lour.) Merr. compound Chinese medicinal preparation of multipath treatment gout and preparation method, can play regulation uric acid metabolism to gout,
Promote urate excretion, prevent uric acid crystal, anti-inflammatory analgetic, control stage of attack arthralgia, swelling and the effect of inflammation, simultaneously
Having regulation blood fat, blood glucose, reduce blood and glue, prevent blood lipid deposition, maintenance cardiovascular and cerebrovascular vessel are healthy, prevent gout complication, specimen
Double controlling reaches anti-antipodagric effect, also has disinfection, improves immunity and metabolic effect.
Claims (7)
1. a Gynura procumbens (Lour.) Merr. compound formulation, it is characterised in that: described compound formulation is made up of following percentage by weight raw material:
Gynura procumbens (Lour.) Merr. 75-85%, Herba Hordei Vulgaris 5-10%, Herba Lophatheri 3-6%, Folium Mori 2-5%, Radix Puerariae 2-4%, Poria 1-3%.
A kind of Gynura procumbens (Lour.) Merr. compound formulation the most according to claim 1, it is characterised in that: described compound formulation is by following
Percentage by weight raw material is made: Gynura procumbens (Lour.) Merr. 77-82%, Herba Hordei Vulgaris 5-8%, Herba Lophatheri 4-5%, Folium Mori 2-4%, Radix Puerariae 2-
3%, Poria 2-3%.
A kind of Gynura procumbens (Lour.) Merr. compound formulation the most according to claim 2, it is characterised in that: described compound formulation is by following
Percentage by weight raw material is made: Gynura procumbens (Lour.) Merr. 80%, Herba Hordei Vulgaris 8%, Herba Lophatheri 4%, Folium Mori 3%, Radix Puerariae 3%, Poria 2%.
4., according to the manufacture method of a kind of Gynura procumbens (Lour.) Merr. compound formulation according to any one of claim 1-3, its feature exists
In: comprise the following steps:
(1) prepare raw material and weigh: choosing fresh, clean Gynura procumbens (Lour.) Merr. base of leaf and whole plant, cleaning and sterilizing；
(2) it is dried, 45-55 DEG C, 30-40min；
(3) calculate with fresh Gynura procumbens (Lour.) Merr. weight, when Gynura procumbens (Lour.) Merr. dehydration is to water content 55-63%, be cut into 0.7-1.5cm
The sections of length, less fire baking, stop when water content 5-10% slightly burnt odor taste bakeing, standby after cooling, particle
Footpath is 1-6mm；
(4) Gynura procumbens (Lour.) Merr. after cooling in Herba Hordei Vulgaris, Herba Lophatheri, Folium Mori, Radix Puerariae, Poria and step (3) is pulverized respectively
Become granule, remix and uniformly become composition of medicine；
(5) by the composition of medicine of above-mentioned mix homogeneously, then be fabricated on request teabag, oral liquid, capsule, tablet, powder,
Granule or the compound formulation of other pharmaceutically acceptable dosage form.
A kind of Gynura procumbens (Lour.) Merr. compound formulation the most according to claim 1, it is characterised in that: described Herba Lophatheri replaces with white
Rhizoma Imperatae, Semen Coicis or Stigma Maydis, Folium Mori replaces with Herba Plantaginis or Herba Lysimachiae.
A kind of Gynura procumbens (Lour.) Merr. compound formulation the most according to claim 1, it is characterised in that: described Radix Puerariae replaces with Rhizoma Dioscoreae
Or the Cortex Eucommiae, Poria replaces with the Radix Astragali or Semen Euryales.
The application of a kind of Gynura procumbens (Lour.) Merr. compound formulation the most according to claim 1, it is characterised in that: described compound formulation
It is applied in the anti-antipodagric preparation of preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410593469.0A CN104366636B (en) | 2014-10-30 | 2014-10-30 | A kind of Gynura procumbens (Lour.) Merr. compound formulation and preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410593469.0A CN104366636B (en) | 2014-10-30 | 2014-10-30 | A kind of Gynura procumbens (Lour.) Merr. compound formulation and preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104366636A CN104366636A (en) | 2015-02-25 |
| CN104366636B true CN104366636B (en) | 2016-07-20 |
Family
ID=52546027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410593469.0A Expired - Fee Related CN104366636B (en) | 2014-10-30 | 2014-10-30 | A kind of Gynura procumbens (Lour.) Merr. compound formulation and preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104366636B (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104758920A (en) * | 2015-04-29 | 2015-07-08 | 唐凯 | Gout health care product based on homology of medicine and food |
| CN105876777A (en) * | 2016-04-12 | 2016-08-24 | 周安琪 | Food having effect of reducing uric acid and preparation technology thereof |
| CN105832794A (en) * | 2016-06-06 | 2016-08-10 | 江西本草天工科技有限责任公司 | Application of Gynura procumbens to production of medicine, healthcare food or functional food for preventing and treating hyperuricemia |
| CN106072560A (en) * | 2016-06-29 | 2016-11-09 | 傅志勇 | A kind of for health product treating gout and preparation method thereof |
| CN106492073A (en) * | 2016-12-30 | 2017-03-15 | 北京万源普达医疗科技有限公司 | A kind of Chinese medicine composition with uric acid resisting effect and its preparation method and application |
| CN106722998A (en) * | 2016-12-30 | 2017-05-31 | 北京万源普达医疗科技有限公司 | A kind of Chinese medicine composition with effect of lowering blood sugar and its preparation method and application |
| CN107050324A (en) * | 2017-01-26 | 2017-08-18 | 赵杏珍 | A kind of integration of drinking and medicinal herbs Chinese medicine function health toxin expelling drink for preventing and treating gout and three high drop |
| CN107296272A (en) * | 2017-07-20 | 2017-10-27 | 钟祥亿源生物科技有限公司 | A kind of anti-trioxypurine composition |
| CN107874060A (en) * | 2017-10-25 | 2018-04-06 | 宁国平衡健康管理有限公司 | A kind of hypoglycemic health food and preparation method thereof |
| CN107753801A (en) * | 2017-12-06 | 2018-03-06 | 周勇 | Anti-trioxypurine, drop purine treat pharmaceutical composition of gout and preparation method thereof |
| CN107897441B (en) * | 2017-12-11 | 2021-03-30 | 江西省科学院应用化学研究所 | Gynura procumbens tea for relieving cough caused by smoking and preparation method thereof |
| CN108096502B (en) * | 2018-01-20 | 2021-02-05 | 南阳仲景百信医药科技有限公司 | Uric acid-reducing substitutional tea and preparation method thereof |
| CN108902980A (en) * | 2018-09-19 | 2018-11-30 | 吉林省恒实传食品科技发展有限公司 | A kind of prevention and treatment hyperuricemia and health care's combined food of gout and preparation method thereof |
| CN110478470A (en) * | 2019-08-28 | 2019-11-22 | 长春中医药大学 | A kind of anti-gout composition of the small-molecular peptides containing sunflower disk and preparation method thereof |
| CN110772611A (en) * | 2019-12-13 | 2020-02-11 | 赵洪勇 | Traditional Chinese medicine composition for regulating gout |
| CN113288977A (en) * | 2021-07-06 | 2021-08-24 | 贵州百灵企业集团制药股份有限公司 | Chinese medicinal preparation for treating acute and chronic kidney diseases and preparation method thereof |
| CN113244341A (en) * | 2021-07-06 | 2021-08-13 | 贵州百灵企业集团制药股份有限公司 | Medicine for treating kidney disease and preparation method thereof |
| CN115350177B (en) * | 2022-08-23 | 2023-06-06 | 暨南大学 | Uric acid reducing function of extract and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101036680A (en) * | 2007-04-08 | 2007-09-19 | 谢平 | Gynura procumbens troche and method for preparing the same |
| CN102366512A (en) * | 2011-09-04 | 2012-03-07 | 成都绿迪科技有限公司 | Traditional Chinese medicinal formula for treating gout |
| CN102908403A (en) * | 2012-11-13 | 2013-02-06 | 广东新大枫化工科技有限公司 | Chinese materia medica preparation for treating gout and preparation method thereof |
| CN103623099A (en) * | 2013-11-28 | 2014-03-12 | 王未境 | Sweet tea used for gout |
| CN104012729A (en) * | 2014-06-11 | 2014-09-03 | 杨平 | Tea substitute bag capable of lowering uric acid |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101361846B1 (en) * | 2013-02-14 | 2014-02-13 | 강원대학교산학협력단 | Atural plant composition for modulate enzyme mrna relate to glucose metabolism in cell |
-
2014
- 2014-10-30 CN CN201410593469.0A patent/CN104366636B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101036680A (en) * | 2007-04-08 | 2007-09-19 | 谢平 | Gynura procumbens troche and method for preparing the same |
| CN102366512A (en) * | 2011-09-04 | 2012-03-07 | 成都绿迪科技有限公司 | Traditional Chinese medicinal formula for treating gout |
| CN102908403A (en) * | 2012-11-13 | 2013-02-06 | 广东新大枫化工科技有限公司 | Chinese materia medica preparation for treating gout and preparation method thereof |
| CN103623099A (en) * | 2013-11-28 | 2014-03-12 | 王未境 | Sweet tea used for gout |
| CN104012729A (en) * | 2014-06-11 | 2014-09-03 | 杨平 | Tea substitute bag capable of lowering uric acid |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104366636A (en) | 2015-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104366636B (en) | A kind of Gynura procumbens (Lour.) Merr. compound formulation and preparation method and application | |
| CN102205107B (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN102526616B (en) | Chinese medicinal herb pills for treating cholecystitis and gallstone | |
| CN102813870B (en) | Chinese herbal compound preparation used for treating alcoholism and gout and preparation method and application thereof | |
| CN106668607A (en) | Traditional Chinese medicine for treating gout | |
| CN105943958A (en) | Inonotus obliquus composite solid particles for treating gout and preparing method thereof | |
| CN104147536A (en) | Medicine composition for treating haemorrhoids and preparation method thereof | |
| CN103893613B (en) | A kind of medicine treating oral ulcer and preparation method | |
| CN104645232A (en) | Traditional Chinese medicine combinatorial composition for treatment of double-flexure syndrome and preparation method and applications thereof | |
| CN103893611A (en) | Drug for treating kidney stone and preparation method of drug | |
| CN112294925A (en) | A medicine for treating gout, gastropathy and constipation, and its preparation method | |
| CN103623291B (en) | Chinese medicine composition of a kind of Therapeutic cancer and preparation method thereof | |
| CN102988747B (en) | Aristida triseta electuary for reducing hypertension, hyperglycemia and hyperlipidemia and preparation method thereof | |
| CN109700006A (en) | Natto enzyme composition | |
| CN102793826B (en) | Traditional Chinese medicine for treating hypertension early-stage kidney damage and preparation method thereof | |
| CN107260866A (en) | It is a kind of to treat Chinese medicine preparation of hemorrhoid and preparation method thereof | |
| CN106309989A (en) | Drug for treating uremia and complication thereof | |
| CN105125945B (en) | A kind of row's stone drink and preparation method thereof for treating kidney stone | |
| CN104083666A (en) | Medicament for treating hemorrhoids and preparation method thereof | |
| CN105687808A (en) | Rhizome bletillae oral liquid capable of stopping bleeding by astringency, and production method thereof | |
| CN104306585A (en) | Traditional Chinese medicine combination for curing prostatitis, and preparation method and application thereof | |
| CN104225343A (en) | Chinese herbal preparation for treating urinary tract infection and preparation method thereof | |
| CN108042725A (en) | A kind of Chinese medicine preparation for treating stone in urinary system and preparation method thereof | |
| CN111467392A (en) | A Chinese medicinal composition for treating or relieving gout | |
| CN103933278A (en) | Preparation method of Tibetan drug for treating gout disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160720 |